Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Drug

Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil

Fineline Cube Nov 7, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...

Company Deals

WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares

Fineline Cube Nov 7, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial

Fineline Cube Nov 7, 2023

Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...

Company Deals Hospital Medical Device

Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery

Fineline Cube Nov 7, 2023

China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic...

Company

Danone Enters China’s Adult FSMP Market with Local Production of Fortimel

Fineline Cube Nov 7, 2023

France-based food company Danone has revealed its strategic plans to enter the adult foods for...

Company Deals

SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China

Fineline Cube Nov 7, 2023

China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...

Company Drug

RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002

Fineline Cube Nov 7, 2023

RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...

Company Drug

Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China

Fineline Cube Nov 7, 2023

The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...

Company Deals

Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA

Fineline Cube Nov 7, 2023

Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with...

Company Deals

Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China

Fineline Cube Nov 7, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a...

Company Medical Device

Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE

Fineline Cube Nov 7, 2023

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group)...

Company Deals

BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal

Fineline Cube Nov 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...

Company Drug

MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries

Fineline Cube Nov 6, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...

Company Deals

Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China

Fineline Cube Nov 6, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Company Deals

CORXEL Partners with WuXi STA for Sterile Nasal Spray Production

Fineline Cube Nov 6, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...

Company Drug

Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management

Fineline Cube Nov 6, 2023

Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...

Company Drug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Fineline Cube Nov 6, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Drug

AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination

Fineline Cube Nov 6, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of...

Deals R&D

HKU and SIIDB Collaborate on Drug Development for Infectious Diseases

Fineline Cube Nov 6, 2023

The Department of Microbiology at the University of Hong Kong (HKU) and the Shanghai Institute...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting

Fineline Cube Nov 6, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...

Posts pagination

1 … 493 494 495 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.